Optimizing Outcomes in High-risk MDS: Current and Emerging Standards of Care

Optimizing Outcomes in High-risk MDS: Current and Emerging Standards of Care
Optimizing Outcomes in High-risk MDS: Current and Emerging Standards of Care
CME, CPE
Eunice S. Wang, MD
Release Date: August 29, 2018
Expiration Date: August 29, 2019

Managing patients with high-risk MDS is complex and requires an approach to therapy that is based on risk stratification to maximize outcomes and minimize toxicity. In this activity, Dr. Wang summarizes strategies for optimizing patient selection and treatment using current standards of care and available data from clinical trials. She also identifies strategies for the appropriate use of hypomethylating agents and discusses clinical trial data that will help guide future directions in managing high-risk MDS patients.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation, Onconova Therapeutics Inc., and Takeda Oncology
Begin, Earn CreditView Only, No CreditGet Certificate
 

MediCom Worldwide, Inc. would like to thank Celgene Corporation and Onconova Therapeutics Inc. for their educational support of ManagingMDS.com

©2018 MediCom Worldwide, Inc. All rights reserved